诺维信在华主要蛋白酶制剂专利技术综述  

Analysis of Patents about Novozyme’s Main Protease Product in China

作　　者：李捷 吴颖 Li Jie;Wu Ying(Patent Examination Cooperation Sichuan Center of the Patent Office,SIPO,Chengdu 610213)

机构地区：[1]国家知识产权局专利局专利审查协作四川中心

出　　处：《山东化工》2019年第16期67-68,共2页Shandong Chemical Industry

摘　　要：诺维信公司(Novozymes)是全球第一大酶制剂企业,也是全球工业酶制剂和生物制剂的主导企业。近些年来,中国已经成为了全球酶制剂市场的战略重点,面对极具发展潜力的中国市场,诺维信公司积极布局,以期在这个正在崛起的市场中抢占更多的市场份额。本文通过检索、统计和分析诺维信公司在中国主要蛋白酶制剂相关的专利申请,对该领域的申请量趋势、申请主题类型以及重点酶制剂产品等进行了统计,并以重点蛋白酶制剂产品为主线梳理了诺维信公司在华有关蛋白酶制剂的技术发展路线。Novozymes is the largest enzyme company in the world,as well as the leading company of the world’s industrial enzyme and biological preparation.In recent years,China has become the strategic focus of enzyme preparation market all over the world.Facing this potent developing market,Novozymes layouts actively in order to capture more marketshare in China.This paper analysed the main protease products applied by Novozymes,and also comb the technical development route or application in China based on main protease products by Novozymes.

关 键 词：诺维信 蛋白酶 专利 

分 类 号：R94[医药卫生—药剂学]